Beta Drugs Ltd
₹1323.70
(0.55%)
Thu, 23 Apr 2026, 05:30 pm
Health Technology
Pharmaceuticals: Major
24.5KBeta Drugs EV/EBITDA Ratio
| Particulars | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 16.11 | 11.26 | 4.08 | 9.84 | 21.90 | 19.62 | 32.55 | 46.61 |
| Price to book ratio | 0 | 0 | 0 | 0 | 0 | 3.31 | 2.21 | 0.67 | 1.68 | 5.89 | 4.90 | 7.55 | 9.76 |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | 2.17 | 1.38 | 0.43 | 1 | 2.96 | 2.66 | 4.01 | 5.46 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 6.69 | 0 | 6.34 | 6.99 | 19.29 | 27.86 | 40.63 | 57.70 |
| Enterprise value | 0 | 0 | 0 | 0 | 0 | 1.05B | 1.08B | 556.37M | 1.22B | 5.47B | 6.04B | 11.72B | 19.68B |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 0 | 11.02 | 9 | 3.06 | 4.91 | 12.74 | 11.19 | 19.53 | 26 |
| Debt to equity ratio | 6.95 | 5.36 | 4.47 | 3.79 | 1.35 | 0.23 | 0.50 | 0.40 | 0.25 | 0.22 | 0.17 | 0.09 | 0.70 |
| Return on equity % | 0 | 12.74 | -18.28 | 69.39 | 103.22 | 33.60 | 21.79 | 19.21 | 18.65 | 30.85 | 28.55 | 26.03 | 23.95 |
Beta Drugs Ltd Enterprise Value to EBITDA Ratio
The Beta Drugs Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Beta Drugs Ltd's valuation, profitability, and overall financial performance. Tracking the Beta Drugs Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Beta Drugs Ltd (NSE: BETA, BSE: 535022) is currently trading at ₹1323.70, with a market capitalization of ₹13.29B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Beta Drugs Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Beta Drugs Ltd Enterprise Value to EBITDA Ratio Current Value
The current Beta Drugs Ltd Enterprise Value to EBITDA Ratio stands at 26.
The latest Beta Drugs Ltd Enterprise Value to EBITDA Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Beta Drugs Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Beta Drugs Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 26
- 2023: 19.53
- 2022: 11.19
- 2021: 12.74
- 2020: 4.91
The recent rise in Beta Drugs Ltd Enterprise Value to EBITDA Ratio suggests strengthening valuation trends and improving market sentiment.
What Beta Drugs Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Beta Drugs Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Beta Drugs Ltd.
Beta Drugs Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Beta Drugs Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Beta Drugs Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Beta Drugs Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800